There is an urgent need for the discovery of biomarkers to be used for the evaluation of pathology in clinical trials, and we are conducting comprehensive analysis in animal models of Duchenne muscular dystrophy, resulting in the identification of many candidate compounds. Our aim is to combine clinical research with gene and cell therapy trials and to use the results to reach commercialization.